Business Segments · Net income attributable to Biogen Inc.
Reportable Segment — Net income attributable to Biogen Inc.
Year-over-year, this metric grew by 32.8%, from $240.50M to $319.50M. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Net income attributable to Biogen Inc. shows a downward trend with a -23.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toNet Income
How to read this metric
An increase indicates improved profitability and operational efficiency, while a decrease suggests margin compression or rising costs.
Detailed definition
This represents the residual profit of the business segment after accounting for all operating expenses, taxes, and non-...
Peer comparison
Comparable to 'Segment Operating Income' or 'Segment Net Profit' at other pharmaceutical firms.
Metric ID:
biib_segment_reportable_segment_net_income_attributable_to_biogen_incHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $761.73M | $761.73M | $761.73M | $761.73M | $290.28M | $290.28M | $290.28M | $290.28M | $393.40M | $583.60M | $388.50M | $266.70M | $240.50M | $634.80M | $466.50M | $0.00 | $319.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -61.9% | +0.0% | +0.0% | +0.0% | +35.5% | +48.3% | -33.4% | -31.4% | -9.8% | +164.0% | -26.5% | -100.0% | — |
| YoY Change | — | — | — | — | -61.9% | -61.9% | -61.9% | -61.9% | +35.5% | +101.1% | +33.8% | -8.1% | -38.9% | +8.8% | +20.1% | -100.0% | +32.8% |
Range$0.00 – $761.73M
CAGR-19.5%
Avg YoY Growth-12.5%
Median YoY Growth-8.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's reportable segment — net income attributable to biogen inc.?
- Biogen (BIIB) reported reportable segment — net income attributable to biogen inc. of $319.50M in Q1 2026.
- How has Biogen's reportable segment — net income attributable to biogen inc. changed year-over-year?
- Biogen's reportable segment — net income attributable to biogen inc. increased by 32.8% year-over-year, from $240.50M to $319.50M.
- What is the long-term trend for Biogen's reportable segment — net income attributable to biogen inc.?
- Over 3 years (2022 to 2025), Biogen's reportable segment — net income attributable to biogen inc. has grown at a -23.9% compound annual growth rate (CAGR), from $3.05B to $1.34B.
- What does reportable segment — net income attributable to biogen inc. mean?
- The final profit generated by the business segment after all associated costs and taxes.